The FDA is investigating reports of suicidal ideation (thoughts) experienced by people taking the drug Chantix which is prescribed to adults to help them stop smoking.
The FDA has also asked the manufacturer, Pfizer,for any information on additional cases that may be similar in patients who have taken the drug since the report citing erratic behavior in an individual who had used Chantix.
FDA’s Center for Drug Evaluation and Research is working to complete an analysis of the available information and data. When this analysis is completed, FDA will communicate the conclusions and recommendations to the public.
In the meantime, FDA recommends that health care providers monitor patients taking Chantix for behavior and mood changes. Patients taking Chantix should contact their doctors if they experience behavior or mood changes.
FDA also advises that, due to reports of drowsiness, patients should use caution when driving or operating machinery until they know how using Chantix may affect them.